Physician profile
Tammy Daniel
NPI 1871221127
$4,053.62
in general payments reported to CMS, 2019-2025
36 companies · $1,742 in 2025
The $1,742 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,312 · 2025: $1,742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,587 · Education: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,586.77 |
| Education | $466.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $328.07 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $317.60 | 2024-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $246.71 | 2024-2025 | Opdivo, Opdualag, Krazati |
| Astrazeneca Pharmaceuticals LP | $225.67 | 2024-2025 | Imfinzi, Calquence, Enhertu |
| Incyte Corporation | $193.09 | 2024-2025 | Jakafi, Zynyz, Monjuvi |
| Celgene Corporation | $181.76 | 2024-2025 | Reblozyl, Opdualag, Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $181.26 | 2024-2025 | |
| Janssen Biotech, INC. | $175.87 | 2024-2025 | Talvey, Darzalex, Erleada |
| Sobi, INC | $174.48 | 2024-2025 | |
| Exelixis INC. | $163.12 | 2024-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $160.36 | 2024-2025 | Jemperli, Ojjaara, Zejula |
| Lilly USA, LLC | $153.98 | 2024 | Verzenio, Jaypirca |
| Novartis Pharmaceuticals Corporation | $138.83 | 2024-2025 | |
| Eisai INC. | $113.02 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.91 | 2024-2025 | Ninlaro, Fruzaqla |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $103.50 | 2024-2025 | Polivy, Venclexta, Gazyva |
| Seagen INC. | $96.00 | 2024 | |
| Gilead Sciences, INC. | $90.81 | 2024-2025 | Trodelvy |
| Pharmaessentia USA Corporation | $85.66 | 2024-2025 | Besremi |
| Regeneron Healthcare Solutions, INC. | $76.98 | 2024-2025 | Libtayo |
| Servier Pharmaceuticals LLC | $70.41 | 2024-2025 | |
| Stemline Therapeutics INC. | $69.43 | 2024-2025 | Orserdu |
| Taiho Oncology, INC. | $69.23 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $68.71 | 2024-2025 | Provenge |
| Genzyme Corporation | $68.57 | 2024-2025 | |
| Astellas Pharma US INC | $54.54 | 2024-2025 | Padcev, Vyloy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.36 | 2024-2025 | |
| Array Biopharma INC | $44.82 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Ipsen Biopharmaceuticals, INC | $44.12 | 2024-2025 | Onivyde, Somatuline Depot |
| Emd Serono, INC. | $42.27 | 2025 | |
| Pharmacosmos Therapeutics INC. | $39.58 | 2024 | Cosela |
| Sumitomo Pharma America, INC. | $34.53 | 2025 | Orgovyx |
| Abbvie INC. | $31.79 | 2024-2025 | |
| Geron Corporation | $23.99 | 2024 | Rytelo |
| Beone Medicines USA, INC. | $17.99 | 2025 | Tevimbra, Brukinsa |
| Novocure INC. | $15.60 | 2025 | Optune Lua (Novottf-200t) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.